Support sexual health

Ovulation and a regular cycle are steps toward pregnancy, not pregnancy. The ovulation pooling was highly inconsistent between trials, and the whole analysis rests on ten small trials totalling 601 women. Neither pooling reported a live birth.

These are the frequent and mild ones, gathered over about twelve weeks. The rare and serious events the label warns about, an erection lasting beyond four hours among them, are too uncommon for trials this size to count, so their absence here is not evidence of their absence.

The two figures come from separate trials rather than one comparison, so the size of the gap is indicative rather than measured. Men in the diabetes trial had lived with it twelve years on average, and response is not broken down by how much nerve or vessel damage they had.

Enrolled men skewed towards mild and moderate erectile dysfunction, so these figures sit at the optimistic end of what an unselected clinic sees. Success was recorded by the men themselves, in diaries. Most trials ran about twelve weeks, and almost all were funded by the manufacturer.

This covers only men who had both nerve bundles spared. Where the nerves were not spared, recovery is substantially worse and these trials say nothing about it. Eight trials, several industry-funded, with dosing and timing after surgery differing between them.

The relative risk of 8.14 runs across an interval from 1.87 to 35.40, which reflects how few men had the event rather than a precise estimate. It rests on four trials, and those trials needed to run only twelve weeks, short against how long testosterone is actually taken.

About 65 men were screened for every one enrolled, so these are not the men who walk into a clinic. One year of treatment is short against how long testosterone is actually taken. In the pooled analysis the sexual-desire interval ran from 0.01 to 0.34, close enough to zero to be worth naming.

The trial was powered for artery thickening rather than for sexual outcomes, so the null on sex is a secondary result rather than a definitive one. Its authors say plainly that it should not be read as establishing cardiovascular safety. Haematocrit and prostate-specific antigen both rose more on testosterone.

Men had to have a partner willing to attempt intercourse at least twice a month, which selects a particular and comparatively motivated group. Twelve outcomes were tested, so some of the ten significant ones may be the arithmetic of testing many things. And the missing threshold cuts both ways: it undercuts any single diagnostic cutoff, and it also means no reading identifies in advance who will benefit.

This is a snapshot, so it can say which symptoms travel with low testosterone and not whether raising it would relieve them. That fatigue and low mood failed to cluster is a statement about how symptoms group, not proof they have nothing to do with testosterone. Testosterone here was measured by mass spectrometry on morning samples, a stricter standard than much routine clinical testing, so the thresholds may not transfer to an ordinary lab result.

The rule is written from blood-pressure measurements, not from counted faints or falls. How much it matters may depend on how long a man has already been on his alpha-blocker, and the review reporting that describes it as suggested rather than settled.

This is a dosing rule read off a label, not a measured harm rate: the label sets the ceiling without publishing what happened to anyone who exceeded it. The three drugs named are examples of a wider group that blocks the same enzyme.

Neither body of evidence included a no-drug arm, so this says which schedule to pick and not whether either beats nothing. The prostatectomy trial took men who were fully potent beforehand and kept both nerve bundles, the group likeliest to recover anyway. A null in 100 men is not equivalence.

A prescribing label sets rules without publishing the data behind them. The starting dose is lower than 50mg for several groups, including anyone already taking a drug that slows sildenafil's clearance.

Thirty-one men in total across two crossover trials, all with stable angina, so the exact size of the fall need not transfer to anyone else. Blood pressure was what these trials counted, not faints, heart attacks or deaths, and a trial counting those in people on nitrates will never be run.

Only 25mg was tested, the lowest marketed strength of sildenafil, so this does not say what 50 or 100mg would do in the same men. Sixty men answering yes or no at home can show the absence of a large effect, not of a small one. The recovery-time result rests on twelve men against four.

A prescribing label sets doses and rules without publishing the data behind them, and its wording is negotiated between a manufacturer and a regulator. Both of these are the US labels, and neither describes what doctors do outside them.

The label states the risk without giving it a size, and puts St John's Wort in the same list as rifampin, a far more powerful enzyme inducer, without ranking them. It covers one product; wording across other combined pills is similar but not identical, and progestogen-only methods are not covered at all.

The mechanism account is an expert review rather than a systematic synthesis, and it describes recovery as highly variable rather than putting numbers on it. Its suggestion that newer short-acting oral and nasal formulations partly spare sperm production is preliminary and rests on no fertility outcomes. The guideline is expert synthesis, and by its own grading many of its recommendations sit on low-quality evidence.

Eleven of the 13 trials in the Cochrane review gave inositol as preparation for in vitro fertilisation, so it does not describe ordinary supplement use. Cochrane translated its own estimate into absolute terms: against a 12% live birth rate without inositol, the rate with it would sit somewhere between 9% and 51%.

Whether inositol raises live births is unsettled. One umbrella review says it more than doubles them, Cochrane calls the outcome too uncertain to judge, and none of the 85 outcomes graded in this field reaches high quality.

These were women undergoing fertility treatment, so this describes a fertility-treatment add-on rather than everyday supplementation. Sixty were randomised and about 44 analysed, a thin base for a gap that wide. There was no plain myo-inositol arm, so it cannot say whether either blend beats myo-inositol on its own. Several of the authors are affiliated with a nutrition-sector company.

The 40:1 ratio the market is built on has been tested far less than the argument over it suggests. The only two trials comparing ratios head to head point opposite ways, and both sit at the lowest certainty rating.

The ranking comes from indirect comparison across trials that never tested these doses against each other, which is far less stable than head-to-head data. Read as advice for one man choosing a dose, it means nothing. Most of the trials underneath it were short and manufacturer-funded.

Every study on both sides is observational, so men who take these drugs differ from men who do not in ways no adjustment removes, sun exposure among them. They also see doctors more often, which alone yields more diagnoses of a cancer found by looking. The newer pooling's studies barely agree.

Men on erectile-dysfunction drugs are diagnosed with melanoma more often. What that means is unsettled: one analysis reads it as shared sun exposure, and a later one urges at-risk men to avoid the drugs without answering that argument.

Two of the five authors have soy-industry ties, one directing an institute funded by the United Soybean Board, and the same group produced the earlier analysis this one updates. Dihydrotestosterone was left out of the pooled outcomes, and it is the one androgen a soy effect has been reported for.

Soy's clean record on male hormones leaves out dihydrotestosterone, the one androgen a crossover trial saw fall by 9 to 15 percent. Both can be true because they measured different things; nobody has pooled the hormone that moved.

Noninferiority means testosterone was not worse than placebo by more than a preset margin, which is a different statement from safe. The three excess events were not adjusted for multiple comparisons and the trial was not powered to find them. Doses were titrated into the low-to-mid normal range, so nothing here speaks to higher amounts. The trial was funded by testosterone manufacturers.

Whether testosterone harms the arteries is unresolved. The largest trial found no rise in major cardiac events; an imaging trial found more non-calcified plaque after a year. Nobody has shown whether that plaque turns into events.

The two-year trial was nested inside a cardiovascular safety study, so every man in it had heart disease or a high risk of it. In the meta-analysis the gain shrank in men with diabetes or obesity, who are a large share of those seeking treatment. And 2.31 points sits close to the smallest difference a man with mild erectile dysfunction would notice.

Whether testosterone helps erections is unsettled. Pooled trials found a gain, largest in men starting lowest; two later long trials found none, in less deficient men on different questionnaires, so the split may be about who was studied.

These were healthy men with normal testosterone taking defined, mostly short courses in contraception trials, not men on open-ended replacement or on the much larger doses used for physique. Recovery was faster with shorter treatment and shorter-acting preparations, both of which cut against long-term replacement. The endpoint is a sperm concentration of 20 million per millilitre, a fertility proxy rather than a pregnancy. The data stop in 2005.

Each man was his own comparison, which handles his fixed characteristics but not a new illness or hospital stay that could prompt both a prescription and a clot. Only 7.8% of the men had a hypogonadism diagnosis code at all. A prescription record shows the drug was dispensed, not that it was taken.

Whether testosterone raises clot risk is unsettled. Insurance claims show about double the odds and the randomised trial no overall excess, yet both point the same way on clots in the lung, the part of the signal that has not gone away.

Recent use carried a higher hazard ratio than current use, 1.60 against 1.25, which points at something other than the drug. The lower edge of the confidence interval sits at 1.01. Exposure was inferred from pharmacy fills, and the finding covers the whole drug class rather than sildenafil alone.

Five observational studies, no randomised evidence, and the risk ratios are not adjusted for the vascular disease that causes both erectile difficulty and this kind of vision loss. The subgroup figures rest on very few cases, because the condition is rare and hard to diagnose in the first place.

Pooled studies found no clear rise in sudden optic-nerve damage for the drug class, yet sildenafil alone came out at about twice the risk. Which holds is open, against a base rate of 2.5 to 11.8 cases per 100,000 men over 50 a year.

The review is narrative rather than systematic, written by a single author with long-standing industry ties in this field and published in a journal supplement. A label naming no interval is not evidence that no interval is safe; it is a regulator declining to guess.

How long after sildenafil a nitrate becomes safe has no agreed answer. One review finds the interaction gone by 24 hours; the US regulator, with the same interaction studies in hand, declines to name any interval.

The arrow could point either way and this design cannot separate them: recreational use may erode confidence, or men who already have difficulty may reach for the drug and call it recreational. The data are from 2006 and 2007, before telehealth prescribing changed how young men get these drugs.

Seventeen women, and although none ovulated, a study this small could not have detected a modest rise in ovulation if there were one. Bleeding was recorded by diary. The hyperforin content of the preparation was never reported, and that is the variable later work shows decides the size of the effect.

Whether St John's Wort lets ovulation break through a combined pill is unsettled. In both trials the pill's hormone levels fell and bleeding rose, but they split on ovulation, and none measured pregnancy.

Thirty-five men at one centre, all young and healthy, so nothing here reaches older men or any clinical outcome. Other hormones moved in inconsistent directions across timepoints, which is what measuring several hormones at three timepoints tends to produce.

This one trial shows dihydrotestosterone falling in 35 young men on soy, with or without isoflavones. It cannot show the fall holds across trials or matters for health; that needs the hormone pooled, which nobody has done.

The zinc came with 5 mg of folic acid a day and there was no zinc-only arm, so neither result can be pinned on the zinc by itself. The men were fertile and subfertile patients at a fertility clinic, not chosen for their zinc status, so this shows what happens when you supplement a mixed group rather than a group known to have enough. Eighty-seven men across four arms is thin enough that this is an effect not detected rather than an effect ruled out.

Eleven men, and every arm of the study sat at or below the 11 mg of zinc a day a man is meant to get, so it compares degrees of going short and never tests giving anyone extra. Thirty-five days at each intake says nothing about years at one. Nothing here shows that a man who already has enough zinc gains anything from more.

How far zinc shortage lowers testosterone is unsettled. An uncontrolled study of four men reported a 73% fall; a controlled feeding study that cut zinc far lower saw 19%. The weaker design produced the figure that travelled.

The restriction arm reported a 73% fall in testosterone from what the paper itself calls marginal restriction, larger than the controlled feeding study found at a far lower intake, which is an anomaly rather than a detail. The supplementation arm recruited men already identified as zinc deficient, so it cannot speak to anyone else. Alongside both sits a correlation measured in 40 men, and a correlation in 40 people is where this began.